Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Coenzyme Q10 (CoQ10) has been investigated as a potential adjunctive treatment for Parkinson’s Disease (PD) primarily due to its role as an antioxidant and its involvement in mitochondrial energy production. Scientific interest began when research showed mitochondrial dysfunction and oxidative stress in the substantia nigra of PD patients. Early pilot studies and a notable 2002 randomized controlled trial suggested that high doses of CoQ10 might slow functional decline in PD patients, generating considerable interest in its neuroprotective potential. However, subsequent larger and more rigorous studies, such as the multicenter Phase III QE3 trial published in 2014, failed to show any significant benefit of CoQ10 supplementation (at doses up to 2400 mg/day) in slowing PD progression compared to placebo. Meta-analyses and systematic reviews consistently conclude that while CoQ10 is generally safe and well-tolerated, there is insufficient evidence to recommend it as a disease-modifying treatment for Parkinson’s Disease. Thus, while there is scientific rationale for its use and it has been studied in clinical trials, the overall quality and consistency of evidence supporting its efficacy is low (rated 2 out of 5). Its use in PD is not based on traditional or folk medicine practices, but rather on modern biomedical hypotheses and clinical research.

More about coenzyme Q10 (CoQ10)
More about Parkinson's Disease

Other ingredients used for Parkinson's Disease

Other health conditions supported by coenzyme Q10 (CoQ10)

Products containing coenzyme Q10 (CoQ10)

Nature's Sunshine Cellular Energy
Nature's Sunshine Circulatory System
Nature's Sunshine Mega-Chel
Nature's Sunshine SnorEase